Targeting the HIV reservoir when starting treatment
Targeting the HIV/SIV reservoir at time of ART initiation
This study is exploring new ways to help people with HIV by trying to wake up hidden virus cells so they can be targeted and destroyed, and if you join, you might get access to exciting new treatments that could really improve your health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10658852 on NIH RePORTER |
What this research studies
This research investigates new methods to eliminate the HIV virus from the body by targeting the viral reservoir at the time when patients begin antiretroviral therapy (ART). It aims to induce the expression of dormant HIV genes in infected individuals, allowing for the targeted destruction of these cells. By combining latency-reversing agents with immune responses, the study seeks to enhance the effectiveness of treatment and potentially lead to a cure for HIV. Patients participating in this research may receive innovative therapies that could significantly change their treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently been diagnosed with HIV and are beginning ART.
Not a fit: Patients who have been living with HIV for many years and are already on long-term ART may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, reducing the need for lifelong treatment.
How similar studies have performed: While the approach of targeting the HIV reservoir is being explored in various studies, this specific method of combining latency-reversing agents with immune responses is relatively novel.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Okoye, Afamefuna — Oregon Health & Science University
- Study coordinator: Okoye, Afamefuna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.